Needham Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $24
Needham analyst Serge Belanger maintains Aerie Pharmaceuticals (NASDAQ:AERI) with a Buy and lowers the price target from $26 to $24.
Aerie Pharmaceuticals Q2 EPS $(0.84) Misses $(0.64) Estimate, Sales $27.20M Beat $26.28M Estimate
Aerie Pharmaceuticals (NASDAQ:AERI) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.64) by 31.25 percent. This is a 20 percent increase over losses of $(1.05) per share
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
18 Key Biopharma Catalysts To Keep An Eye On In Q3
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months.
Needham analyst Serge Belanger highlighted companies in the firm's coverage universe that have key catalysts in the third quarter.
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.
Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell
• Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.